Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

EMA to Seek New Home after Brexit Vote

By Ryan Bushey | June 27, 2016

Britain’s historic vote to leave the European Union (EU) last week shocked the world as financial markets plunged in reaction to a decision no one expected.

It could take years to fully comprehend what this moment signifies for the global economy, but the European Medicines Agency (EMA) is one institution facing a particularly uncertain future after this referendum.

The EMA, currently headquartered in London, will need to seek a new home that is still part of the European Union in order to continue fulfilling its regulatory duties when it comes to drug approvals, wrote Politico.  The agency serves as an important stop for drug makers seeking marketing approval for new treatments in Europe.

Sweden, Denmark, and Italy are some of the locales that have expressed interest in housing the EMA.

An estimated 840 regulators and scientists are employed by the EMA and setting up a new base in an area with strong inter-EU connections would be beneficial when it comes to expert input regarding committee meetings, according to Politico.

But this move could be complicated.  

“Industry executives fear upheaval at the EMA could snarl the EU’s drug approval process and Britain may have to develop its own domestic regulatory system, leading to further confusion,” reported Reuters.

Furthermore, a scenario of this nature would mean drug companies would prioritize launching new medications in the EU market instead of Britain’s.

The country’s exit from the EU will be a long negotiation process, but it’s still unknown how things will play out.

However, politicians and business leaders from all over the world are calling for an orderly transition.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50